三月 2026
- Home
- InSilico Medicine, Inc.
三月 2026的InSilico Medicine, Inc.市场份额分析
Generative AI and Automation for Longevity and Sustainability
InSilico Medicine, Inc.(包含公司地区分支机构)
查看更多网站流量和参与度信息- insilico.com
InSilico Medicine, Inc.收入截至 三月 2026为 25M - 50M
InSilico Medicine, Inc.主要域名产生的收入
3 年中InSilico Medicine, Inc.主要域名的收入
InSilico Medicine, Inc.主要域名的收入
InSilico Medicine, Inc.热门域名的总访问量
了解InSilico Medicine, Inc.市场份额和潜在市场覆盖范围。
过去 3 个月的总访问量
子公司明细
InSilico Medicine, Inc.热门域名的平均访问时长
分析InSilico Medicine, Inc.参与度指标。
过去 3 个月的平均访问时长
子公司明细
InSilico Medicine, Inc.热门域名的平均页面浏览量
了解InSilico Medicine, Inc.如何保持用户参与度、培养用户兴趣和鼓励采取后续操作。
过去 3 个月的平均页面浏览量
子公司明细
想要获取更深入的流量洞见?
过滤超过 2030 万家在线企业。发现流量激增的新潜在客户,开始或停止使用技术的新潜在客户,或者获得正面报道的新潜在客户。
InSilico Medicine, Inc. 的新闻与信号
借助 Similarweb 销售信号提醒,每当在目标受众之中出现新的机会或威胁时,您都会收到所识别出购买信号的每日更新。
新闻Insilico Medicine, Inc. launches advancements to unified AI framework for drug target discovery.Insilico Medicine, a clinical-stage biotechnology company powered by generative artificial intelligence (AI), today announced advancements to its unified AI framework for drug target discovery, integrating its previously introduced Target Identification Pro (TargetPro) and Target Identification Benchmark (TargetBench 1.0) into a validated system designed to improve the accuracy, reliability, and scalability of early-stage drug development.
四月 30, 2026阅读更多
新闻Insilico Medicine, Inc. is developing pipeline of drugs discovered using artificial intelligence on Mar 1st '26.Eli Lilly, in the race with Novo Nordisk to lead the weight-loss drug market, announced a partnership with Insilico Medicine in March 2026 to develop and commercialise medicines discovered using artificial intelligence.
四月 14, 2026阅读更多
新闻Insilico Medicine, Inc. is developing deep learning for end-to-end drug discovery."From its inception, Insilico Medicine has been developing deep learning for end-to-end drug discovery.
三月 30, 2026阅读更多
查看 InSilico Medicine, Inc. 的所有信号
让您的销售团队专注于最有希望的机会。通过分清机会的轻重缓急并在合适的时机介入,您可以优化工作并达成更多交易。
